NCT00316433View on ClinicalTrials.gov

Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

February 28, 2005

Study Completion Date

January 31, 2007

Conditions

Small Cell Lung Cancer

Interventions

DRUG

Irinotecan (CPT-11)

DRUG

Oxaliplatin (Eloxatin)

Trial Locations (1)

98104

Swedish Medical Center Cancer Institute, Seattle

Sponsors

Collaborators (1)

Sanofi-Synthelabo

All Listed Sponsors

collaborator

Sanofi-Synthelabo

INDUSTRY

lead

Swedish Medical Center

OTHER